Targeting NBPF7P for Neuroblastoma Treatment (G343505)

Target Name: NBPF7P

NCBI ID: G343505

NBPF7P

Targeting NBPF7P for Neuroblastoma Treatment

Neuroblastoma, also known as a neurofibromatous tumor, is a type of cancer that affects the nervous system. It is characterized by the formation of tumors that develop from nerve cells, and they can be found in various parts of the body, including the brain, spinal cord, and gastrointestinal tract. Despite being a relatively common type of cancer, neuroblastomas are often treated with difficulty, and there is a high demand for new treatments.

One potential drug target for neuroblastomas is the Neuroblastoma Breakpoint Family member 7 (NBPF7P). This protein is a key regulator of the neural stem cell lineage, and it has been shown to play a role in the development and progression of neuroblastomas.

The Neuroblastoma Breakpoint Family member 7 (NBPF7P) is a transmembrane protein that is expressed in a wide range of tissues, including the brain, spinal cord, and gastrointestinal tract. It is a member of the TGF-β signaling pathway, which is a well-known regulator of cell growth and differentiation.

NBPF7P is involved in the regulation of several key processes in neuroblastoma development, including cell proliferation, differentiation, and survival. It has been shown to play a role in the development of neuroblastoma-initiating stem cells, as well as in the regulation of neuroblastoma stem cell proliferation and differentiation.

In addition to its role in neuroblastoma development,NBFP7P has also been shown to be a potential drug target for the treatment of neuroblastomas. By inhibiting the activity of NBPF7P, researchers have found that they can reduce the growth and spread of neuroblastomas in animal models.

The potential benefits of targeting NBPF7P with drugs are significant. If NBPF7P were to be successfully targeted, it could potentially lead to a more effective treatment of neuroblastomas. Additionally, by studying the role of NBPF7P in neuroblastoma development, researchers may be able to identify new targets for the development of more effective therapies for this disease.

In conclusion, the Neuroblastoma Breakpoint Family member 7 (NBPF7P) is a promising drug target for the treatment of neuroblastomas. Further research is needed to fully understand the role of NBPF7P in neuroblastoma development and to identify effective therapies that target this protein.

Protein Name: NBPF Member 7, Pseudogene

The "NBPF7P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NBPF7P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets